Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADILNASDAQ:PBLANASDAQ:PTPINASDAQ:SNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$0.68$0.69$0.57▼$3.00$5.37M1.211.10 million shs40,378 shsPBLAPanbela Therapeutics$0.28-3.5%$0.29$0.23▼$0.48$1.36M1.3418,959 shs990 shsPTPIPetros Pharmaceuticals$0.04-7.4%$0.92$0.02▼$17.00$1.09M1.943.09 million shs578,359 shsSNPXSynaptogenix$2.28+5.3%$2.31$1.84▼$5.05$3.16M1.0622,070 shs11,100 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+1.49%-4.47%-4.76%-11.69%-44.26%PBLAPanbela Therapeutics+19.44%+20.88%+11.41%-30.95%-32.56%PTPIPetros Pharmaceuticals+12.46%-42.92%-97.38%-98.53%-99.75%SNPXSynaptogenix-5.88%-4.64%-11.48%-21.60%-52.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial Pharmaceuticals2.8035 of 5 stars3.83.00.00.03.10.01.3PBLAPanbela TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APTPIPetros Pharmaceuticals1.2606 of 5 stars0.05.00.00.02.60.80.6SNPXSynaptogenix2.5655 of 5 stars3.55.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial Pharmaceuticals 3.50Strong Buy$8.001,076.47% UpsidePBLAPanbela Therapeutics 2.00HoldN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/ASNPXSynaptogenix 3.00Buy$14.00515.38% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/APTPIPetros Pharmaceuticals$5.11M0.21N/AN/A$4.04 per share0.01SNPXSynaptogenixN/AN/AN/AN/A$25.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$1.46N/AN/AN/AN/A-168.25%-148.46%8/12/2025 (Estimated)PBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%6/5/2025 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$119.00N/A∞N/AN/A-78.22%-23.50%N/ASNPXSynaptogenix-$6.04M-$10.08N/A∞N/AN/A-42.14%-29.42%N/ALatest ADIL, SNPX, PTPI, and PBLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/A5/15/2025Q1 2025SNPXSynaptogenixN/A$0.04N/A$0.04N/AN/A5/14/2025Q1 2025ADILAdial Pharmaceuticals-$0.50-$0.34+$0.16-$0.34N/AN/A3/27/2025Q4 2024SNPXSynaptogenix-$2.06-$4.36-$2.30-$4.36N/AN/A3/4/2025Q4 2024ADILAdial Pharmaceuticals-$0.38-$0.15+$0.23-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A6.786.78PBLAPanbela TherapeuticsN/A0.260.26PTPIPetros Pharmaceuticals1.580.850.74SNPXSynaptogenixN/A65.3465.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%PBLAPanbela Therapeutics4.37%PTPIPetros Pharmaceuticals12.34%SNPXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals5.24%PBLAPanbela Therapeutics0.01%PTPIPetros Pharmaceuticals12.25%SNPXSynaptogenix2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals207.90 million6.07 millionNo DataPBLAPanbela Therapeutics64.86 million4.86 millionNot OptionablePTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableSNPXSynaptogenix41.39 million1.32 millionNot OptionableADIL, SNPX, PTPI, and PBLA HeadlinesRecent News About These CompaniesSynaptogenix (NASDAQ:SNPX) Trading 1.5% Higher - Here's What HappenedMay 28 at 2:57 AM | americanbankingnews.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024August 16, 2024 | investorplace.comSynaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord InjuryJuly 19, 2024 | markets.businessinsider.comSynaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryJuly 18, 2024 | prnewswire.comSynaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisJune 26, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024May 20, 2024 | investorplace.comSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryMay 7, 2024 | prnewswire.comSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | finanznachrichten.deSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | prnewswire.comSynaptogenix announces reverse stock split to regain Nasdaq complianceApril 5, 2024 | uk.investing.comWhat's Going On With Synaptogenix (SNPX) Stock?April 4, 2024 | msn.comSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingApril 3, 2024 | finance.yahoo.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%February 22, 2024 | msn.comSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersDecember 19, 2023 | finance.yahoo.comSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sDecember 6, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADIL, SNPX, PTPI, and PBLA Company DescriptionsAdial Pharmaceuticals NASDAQ:ADIL$0.68 0.00 (0.00%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Panbela Therapeutics NASDAQ:PBLA$0.28 -0.01 (-3.52%) As of 09:51 AM EasternPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Petros Pharmaceuticals NASDAQ:PTPI$0.04 0.00 (-7.39%) As of 11:13 AM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Synaptogenix NASDAQ:SNPX$2.28 +0.12 (+5.32%) As of 11:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
